Press release: VivoPlex Clinical Stage funding round brings £3.9m for product development

VivoPlex Clinical Stage funding round brings £3.9m for product development

Clinical study of intra-uterine sensor to generate European approval data

Oxford, UK, August 4 2020 – VivoPlex Group Ltd, which is transforming fertility treatment and women’s health via intra-uterine sensing, has raised £3.9m in its Clinical Stage financing round. The funds, which were raised in two tranches, will be used to complete the first clinical feasibility study of its wireless battery-free uterine sensor system. The study is expected to generate key clinical data to support European approval (CE marking) for the company’s first product.

The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation. Developed by the Government and delivered by the British Business Bank, the Future Fund supports high potential innovative businesses in the UK currently affected by Covid-19.

In line with other medical device and pharmaceutical companies, the clinical feasibility study will start as soon as practicably possible after capacity becomes available post the COVID-19 lockdown.

Joanna Smart, CEO of VivoPlex, said ‘The close of our Clinical Stage funding round enables us to continue development of our intra-uterine sensor platform and bring our first product to market, and we would like to thank all our supporters, including the Future Fund. The field of women’s health needs better tools to support evidence-based clinical decisions and we at VivoPlex are excited to have developed a technology that can provide valuable insights to doctors.’


For further information, please contact:

Joanna Smart, CEO

Tel: +44 (0) 2380 111555

Emma Palmer Foster, Communications

Tel: +44 (0) 7880 787185


Notes to editors

VivoPlex Group Ltd

VivoPlex is a transformative health technology company focused on human fertility and women’s health. With a novel approach to monitoring the uterine environment, it is expected to drastically change the dynamics of the fertility treatment sector and improve the understanding of women’s health. The products in development represent the first insertable wireless devices for the measurement of key uterine parameters – oxygen concentration, pH and temperature – in vivo.

The VivoPlex product comprises an insertable monitor no bigger than an intra-uterine device (IUD or coil) plus a wearable in the form of washable, discreet briefs which provides wireless power to the device and transmits data to proprietary software for use by the clinical specialist. It has generated positive results in early studies. The company, which brings together a multidisciplinary team of clinical fertility experts and world-class biosensor and digital technology engineers with experienced corporate and business development executives, was established in 2015 as a spin-out from the University of Southampton. For more information please visit